Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Potent Inhibition of Cytochrome P-450 2D6-Mediated Dextromethorphan O-Demethylation by Terbinafine

Susan M. Abdel-Rahman, Kenda Marcucci, Thomas Boge, R. Russell Gotschall, Gregory L. Kearns and J. Steven Leeder
Drug Metabolism and Disposition July 1999, 27 (7) 770-775;
Susan M. Abdel-Rahman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenda Marcucci
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Boge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Russell Gotschall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory L. Kearns
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Steven Leeder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Cytochrome P-450 (CYP) 2D6 is responsible for the biotransformation of over 35 pharmacologic agents. In the process of studying CYP2D6 we identified phenotype-genotype discordance in two individuals receiving terbinafine. This prompted evaluation of the potential for terbinafine to inhibit CYP2D6 in vitro. Human hepatic microsomes and heterologously expressed CYP2D6 were incubated with terbinafine or quinidine and the formation of dextrorphan from dextromethorphan was determined by HPLC. Additionally, preliminary conformational analyses were conducted to determine the fit of terbinafine into a previously described pharmacophore model for CYP2D6 inhibitors. The apparentKm and Vmax of dextrorphan formation from four human hepatic microsome samples ranged from 5.8 to 6.8 μM and from 172 to 300 pmol/min/mg protein, respectively. Values of Km andVmax in the heterologously expressed CYP2D6 system averaged 6.5 ± 2.1 μM and 1342 ± 147 pmol/min/mg protein, respectively. Terbinafine inhibited dextromethorphanO-demethylation with an apparentKi ranging from 28 to 44 nM in human hepatic microsomes and averaging 22.4 ± 0.6 nM for the heterologously expressed enzymes. Results of quinidine in these systems produced values for Ki ranging from 18 to 43 nM. Such strong inhibition of CYP2D6 by terbinafine would not have been predicted by the previously proposed pharmacophore model of CYP2D6 inhibitors based on molecular structure. Terbinafine is a potent inhibitor of CYP2D6 with apparent Ki values well below plasma and tissue concentrations typically achieved during a therapeutic course. This agent needs to be evaluated in vivo to determine the impact of CYP2D6 inhibition by terbinafine on the metabolism of concomitantly administered CYP2D6 substrates.

Footnotes

  • Send reprint requests to: Dr. Susan Abdel-Rahman, Section of Pediatric Clinical Pharmacology and Experimental Therapeutics, The Children’s Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108. E-mail: srahman{at}cmh.edu

  • This work was supported in part by Grant 1UO1 HD 31313–06 (Network of Pediatric Pharmacology Research Units) from the National Institute of Child Health and Human Development, Bethesda, MD.

  • Abbreviations used are::
    CYP
    cytochrome P-450
    DM
    dextromethorphan
    DX
    dextrorphan
    • Received October 8, 1998.
    • Accepted March 29, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (7)
Drug Metabolism and Disposition
Vol. 27, Issue 7
1 Jul 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Potent Inhibition of Cytochrome P-450 2D6-Mediated Dextromethorphan O-Demethylation by Terbinafine
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Potent Inhibition of Cytochrome P-450 2D6-Mediated Dextromethorphan O-Demethylation by Terbinafine

Susan M. Abdel-Rahman, Kenda Marcucci, Thomas Boge, R. Russell Gotschall, Gregory L. Kearns and J. Steven Leeder
Drug Metabolism and Disposition July 1, 1999, 27 (7) 770-775;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Potent Inhibition of Cytochrome P-450 2D6-Mediated Dextromethorphan O-Demethylation by Terbinafine

Susan M. Abdel-Rahman, Kenda Marcucci, Thomas Boge, R. Russell Gotschall, Gregory L. Kearns and J. Steven Leeder
Drug Metabolism and Disposition July 1, 1999, 27 (7) 770-775;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A PBPK model for CBD in adults and children
  • Antibiotics Induce Changes in the Expression of Rat DPGs
  • Metabolism of Efavirenz by P450s and UGTs in the Brain
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics